raulgainetdinov

Download CV

Personal Websites

Raul Gainetdinov

Professor
Center for Functional Genomics

Prior to Skoltech, Raul was an Associate Research Professor in the Department of Cell Biology, Duke University in North Carolina, USA where he is currently an Adjunct Associate Professor. Since 2008, he is also Senior Researcher in the Department of Neuroscience and Brain Technologies at the Italian Institute of Technology in Genova, Italy and since 2013 he is Professor of the Faculty of Biology and Soil Sciences, St. Petersburg State University, St. Petersburg, Russia. Before joining the Department of Cell Biology in 1996 and becoming faculty at Duke in 2000, he conducted research at the Institute of Pharmacology Russian Academy of Medical Sciences in Moscow (1988-1996). He received a Ph.D. degree in pharmacology in 1992 from the Russian Academy of Medical Sciences and a doctor of medicine degree in 1988 from the Second Moscow Medical Institute, Moscow, Russia.

His major research interests focus on translational neuroscience and molecular pharmacology of monoaminergic signaling in experimental animal models of brain pathology (ADHD, schizophrenia, addiction, Parkinson’s disease). In 2013, Raul has been elected Chair of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) subcommittee for the Dopamine receptors family. Raul is a member of several grant committees worldwide, reviewer of a number of international scientific journals and serves in the Editorial Board of Scientific Reports (Nature Publishing Group). Raul has been consulting several major international pharmaceutical companies and he is co-founder of start-up biotech companies in USA (Axitare Inc.) and Russia (IllGene inc., RegMedLab Inc.) that recently received resident status at the Skolkovo Innovation Center.  He has received several research awards and authored more than 170 publications and 9 US patents and patent applications. His work has been cited more than 11,500 times and his current H-index is 57.

  • Classical monoamines and trace amines in physiology and pathology
  • Dopamine transporters, receptors, signal transduction and GPCR regulatory mechanisms in dopamine-related functions and behaviors
  • Molecular mechanisms of action of psychotropic drugs (psychostimulants, antipsychotics, antidepressants, mood stabilizers, cognitive enhancers)
  • Genetic animal models of brain disorders (ADHD, addiction, depression, Parkinson’s disease, schizophrenia)
  • Transgenic technologies in pharmacology
  • Gainetdinov RR, Fumagalli F, Jones SR, Caron MG.  Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. (1997) 69: 1322-1325.
  • Bosse R, Fumagalli F, Jaber M, Giros B,Gainetdinov RR, Wetsel WC, Missale C, Caron MG.  Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron (1997) 19: 27-138.
  • Wang Y-M,Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB, Miller GW, Wightman RM, Caron MG.  Knockout of the Vesicular Monoamine Transporter-2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron (1997) 19: 1285-1296.
  • Gainetdinov RR, Jones SR, Fumagalli F, Wightman RM, Caron MG.  Re-evaluation of the role of dopamine transporter in dopamine system homeostasis. Brain Research Reviews (1998) 26: 148-153.
  • Jones SR,Gainetdinov RR, Wightman RM, Caron MG.  Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA (1998) 95: 4029-4034.
  • Gainetdinov RR,Fumagalli F, Wang Y-M, Jones SR, Levey AI, Miller GW, Caron MG.  Increased MPTP neurotoxicity in Vesicular Monoamine Transporter 2 heterozygote knockout mice. J. Neurochem. (1998) 70: 1973-1978.
  • Rocha BA, Fumagalli F,Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW, Caron MG.  Cocaine self-administration in dopamine transporter knockout mice. Nature Neuroscience (1998) 1: 132-137.
  • Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science (1999) 283: 397-401.
  • Gainetdinov RR, Bohn LM, Walker JKL, Laporte SA, Macrae AD, Caron MG, Lefkowitz RJ, Premont RT. Muscarinic supersensitivity and impaired desensitization in G protein – coupled receptor kinase 5 – deficient mice. Neuron (1999) 24: 1029-1036.
  • Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell (1999) 98: 427-436.
  • Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin F-T. Enhanced Morphine Analgesia in mice lacking beta-Arrestin 2. Science (1999) 286: 2495-2498.
  • Jones SR, Gainetdinov RR, Hu X-T, Cooper DC, Wightman RM, White FJ, Caron MG.  Loss of autoreceptor functions in mice lacking the dopamine transporter. Nature Neuroscience (1999) 2: 649-655.
  • Bohn LM, Gainetdinov RR, Lin F-T, Lefkowitz RJ, Caron MG. Mu-Opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature (2000) 408: 720-723.
  • Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, Wang YM Caron MG. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nature Neuroscience (2000) 3: 465-71.
  • Gainetdinov RR and Caron MG. An animal model of attention deficit hyperactivity disorder. Molecular Medicine Today (2000) 6: 43-44.
  • Gainetdinov RR, Mohn AR, Bohn LM, Caron MG. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci USA (2001) 98: 11047-11054.
  • Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends in Neurosciences (2001) 24: 527-533.
  • Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R.  Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA (2001) 98:1982-1987.
  • Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S.  Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA (2001) 98: 15312-15317.
  • Gainetdinov RR, Sotnikova TD, Caron MG. Monoamine transporter pharmacology and mutant mice. Trends in Pharmacological Sciences 2002, 23: 367-373.
  • Laakso A, Mohn AR, Gainetdinov RR, Caron MG.  Experimental genetic approaches to addiction. Neuron (2002) 36: 213-228.
  • Gainetdinov RR, Bohn LM, Sotnikova TD, Cyr M, Laakso A, Macrae AD, Torres GE, Kim KM, Lefkowitz RJ, Caron MG, Premont RT. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron (2003) 38: 291-303.
  • Cyr M, Beaulieu JM, Laakso A, Sotnikova TD, Yao WD, Bohn LM,Gainetdinov RR,Caron MG.  Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic output neurons. Proc Natl Acad Sci USA (2003) 100: 11035-11040.
  • Gainetdinov RR and Caron MG. Monoamine transporters: from genes to behavior. Annual Rev Pharmacol Toxicol (2003) 43: 261-284.
  • Torres GE, Gainetdinov RR, Caron MG.  Plasma membrane monoamine transporters: structure, regulation and function. Nature Review Neuroscience (2003) 4: 13-25.
  • Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD, Zeng H, Caron MG, Tonegawa S.  Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci USA(2003) 100: 8987-8992.
  • Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG. Tryptophan Hydroxylase-2 Controls Brain Serotonin Synthesis. Science (2004), 305: 217.
  • Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annual Rev Neurosci (2004) 27: 107-144.
  • Yao WD, Gainetdinov RR, Arbuckle MI, Sotnikova TD, Cyr M, Beaulieu JM, Torres GE, Grant SGN, Caron MG.  Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron (2004) 41: 625-638.
  • Sotnikova TD, Budygin EA, Jones SR, Dykstra LA, Caron MG,Gainetdinov RR. Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. J Neurochem (2004) 91: 362-373.
  • Budygin EA, Brodie MS, Sotnikova TD, Mateo Y, John CE, Cyr M, Gainetdinov RR, Jones SR. Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine. Proc Natl Acad Sci USA (2004) 101: 7781-7786.
  • Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG. Lithium antagonizes dopamine dependent behaviors through an AKT/Glycogen Synthase Kinase 3 signaling cascade. Proc Natl Acad Sci USA (2004) 101:5099-5104.
  • Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG, Gainetdinov RR. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol. (2005) 3: e271.
  • Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell (2005) 122: 261-273.
  • Zhang X, Gainetdinov RR, Beaulieu JM, Sotnikova TD, Burch LH, Williams RB, Schwartz DA, Krishnan KRR, Caron MG.  Loss-of-function mutation in Tryptophan Hydroxylase-2 identified in unipolar major depression. Neuron (2005) 45: 11-16.
  • Sotnikova TD, Caron MG, Gainetdinov RR. DDD mice, a novel acute mouse model of Parkinson’s disease. Neurology (2006) 67: S12-S17.
  • Costa RM, Lin S-C, Sotnikova TD, Cyr M,Gainetdinov RR, Caron MG, Nicolelis MAL. Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron (2006) 52: 359-369.
  • Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG. Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J Biol Chem (2006) 281: 32072-32080.
  • Prado VF, Martins-Silva C , de Castro BM, Lima RF, Barros DM, Amaral E, Ramsey AJ, Sotnikova TD, Ramirez MR, Kim H-G, Rossato JI,  Koenen J, Quan H, Cota VR , Moraes MFD, Gomez MV, Guatimosim C, Wetsel WC, Kushmerick C, Pereira GS, Gainetdinov RR,  Izquierdo IA, Caron MG, Prado MAM. Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron (2006) 51, 601-12.
  • Premont RT and Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Annual Rev Physiol (2007) 69: 511-534.
  • Beaulieu JM,Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci (2007) 28: 166-172.
  • Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG. A b-arrestin 2 signaling complex mediates lithium action on behavior. Cell (2008) 132: 125-136.
  • Gainetdinov RR. Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn-Schmiedeberg’s Archives of Pharmacology (2008) 377: 301-313.
  • de Araujo IE, Oliveira-Maia AJ, Sotnikova TD, Gainetdinov RR, Caron MG, Nicolelis MAL, Simon SA. Food reward in the absence of taste receptor signaling. Neuron (2008) 57: 930-41.
  • Salahpour A, Medvedev IO, Ramsey AJ, Kile B, Sotnikova TD, Holmstrand E, Ghisi V, Wong L, Murphy K, Sesack SR, Wightman RM, Gainetdinov RR, Caron MG. Increased amphetamine-induced hyperactivity and reward in mice over-expressing the dopamine transporter. Proc Natl Acad Sci USA (2008) 105: 4405-10.
  • Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, Gainetdinov RR, Caron MG. Role of GSK3b in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA (2008) 105: 1333-1338.
  • Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM,Gainetdinov RR, Caron MG. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA (2008) 105: 13656-61.
  • Barak LS, Salahpour A, Zhang X, Masri B, Sotnikova TD, Ramsey AJ, Violin JD, Lefkowitz RJ, Caron MG, Gainetdinov RR. Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol Pharmacol (2008) 74: 585-94.
  • Sotnikova TD, Caron MG, Gainetdinov RR. Trace amine associated receptors (TAARs) as emerging therapeutic targets. Mol Pharmacol (2009) 76: 229-35.
  • Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 Signaling in the Action of Psychotropic Drugs. Annu Rev Pharmacol Toxicol (2009) 49: 327-47.
  • Sotnikova TD and Gainetdinov RR. Octopamine and other monoamines in invertebrates. In book: Encyclopedia of Neuroscience (Ed. L.Squire), Elsevier, Oxford, UK, 2009, Vol. 7, pp. 9-15.
  • Gainetdinov RR. Strengths and limitations of genetic models of ADHD. ADHD Atten Def Hyp Disord (2010) 2:21–30.
  • Sotnikova TD, Beaulieu JM, Espinoza S, Masri B, Zhang X, Salahpour A, Barak LS, Caron MG, Gainetdinov RR. The dopamine metabolite 3-methoxytyramine is a neuromodulator. PLoS One (2010) 5: e13452.
  • Caron MG and Gainetdinov RR. Role of Dopamine Transporters in Neuronal Homeostasis. In book: Dopamine Handbook (Eds. L. Iversen, S. Iversen, S. Dunnett, A. Bjorklund) Oxford University Press, New York, USA, 2010, pp. 88-99.
  • Beaulieu JM and Gainetdinov RR. The Physiology, Signaling and Pharmacology of Dopamine Receptors. Pharmacological Reviews (2011) 63: 182-217.
  • Beaulieu JM, Del’Guidice T, Sotnikova TD, Lemasson M, Gainetdinov RR. Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors. Frontiers in Molecular Neuroscience (2011) 4: 38.
  • Espinoza S, Salahpour A, Masri B, Sotnikova TD, Messa M, Barak LS, Caron MG, Gainetdinov RR. Functional interaction between Trace Amine Associated Receptor 1 (TAAR1) and dopamine D2 receptor. Mol Pharmacol (2011) 80: 416-25.
  • Caiazzo M, Dell’anno MT, Dvoretskova E, Lazarevic D, Taverna S, Leo D, Sotnikova TD, Menegon A, Roncaglia P, Colciago G, Russo G, Carninci P, Pezzoli G, Gainetdinov RR, Gustincich S, Dityatev A, Broccoli V. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature (2011) 476: 224-7.
  • Herrmann R, Heflin SJ, Hammond T, Lee B, Wang J, Gainetdinov RR, Caron MG, Eggers ED, Frishman LJ, McCall MA, Arshavsky VY. Rod vision is controlled by dopamine-dependent sensitization of rod bipolar cells by GABA. Neuron (2011) 72: 101-10.
  • Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, Durkin S, Zbinden KG, Norcross R, Meyer CA, Metzler V, Chaboz S, Ozmen L, Trube G, Pouzet B, Bettler B, Caron MG, Wettstein JG, Hoener MC. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A (2011) 108: 8485-90.
  • Guzman MS, De Jaeger X, Raulic S, Souza IA, Li AL, Schmid S, Menon RS,  Gainetdinov RR, Caron MG,  Bartha R, Prado VF, Prado MAM. Elimination of the vesicular acetylcholine transporter in the striatum reveals regulation of behaviour by cholinergic-glutamatergic co-transmission. PLOS Biology (2011) 9:  e1001194.
  • Espinoza S, Managò F, Leo D, Sotnikova TD, Gainetdinov RR. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson’s disease and L-DOPA treatment. CNS & Neurological Disorders – Drug Targets (2012) 11:251-63.
  • Managò F, Espinoza S, Salahpour A, Sotnikova TD, Caron MG, Premont RT, Gainetdinov RR. The role of GRK6 in animal models of Parkinson’s disease and L-DOPA treatment. Sci Rep. (2012) 2: 301.
  • Lavoie J, Illiano P, Sotnikova TD, Gainetdinov RR, Beaulieu JM, Hébert M. The electroretinogram as a biomarker of central dopamine and serotonin: potential relevance to psychiatric disorders. Biol Psychiatry (2013) [in press].
  • Siesser WB, Sachs BD, Ramsey AJ, Sotnikova TD, Beaulieu JM, Zhang X, Caron MG,  Gainetdinov RR. Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice. ACS Chemical Neuroscience (2013) 4: 84-88.
  • Theka I, Caiazzo M, Dvoretskova E, Leo D, Ungaro F, Curreli F, Managò F, Pezzoli G, Gainetdinov RR, Dityatev A and Broccoli V. Rapid generation of functional dopaminergic neurons from human iPS cells through a single step procedure employing cell lineage transcription factors. Stem Cells Translational Medicine (2013) 2: 473-9.
  • Espinoza S, Masri B, Salahpour A, Gainetdinov RR. BRET approaches to characterize dopamine and TAAR1 receptor pharmacology and signaling. Methods Mol Biol (2013) 964: 107-122.
  • Leo D and Gainetdinov RR. Transgenic mouse models for ADHD. Cell Tissue Res. (2013) 354: 259-71.
  • 1993 – Young investigator award from the International Society for Neurochemistry
  • 1997 – Post-doctoral Research Award from the Tourette Syndrome Association, Inc.
  • 2005 – Research Award from the Michael J. Fox Foundation for Parkinson’s  Research
  • 2006 – Research Award from the Michael J. Fox Foundation for Parkinson’s  Research
  • 2008 – Research Award from F. Hoffmann-La Roche Ltd., Basel, Switzerland
  • 2009 – Research Award from Compania di San Paolo Fondaziona, Torino, Italy
  • 2011 – Research Award from F. Hoffmann-La Roche Ltd., Basel, Switzerland
  • 2012 – Research Award from F. Hoffmann-La Roche Ltd., Basel, Switzerland
  • 2013 – elected Chair of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) subcommittee for the Dopamine receptors family
evgeniyaefimova
Evgeniya Efimova
Research Scientist
Neuroscience

Number of ECTS credits: 3
Course Classification: Science, Technology, and Engineering

Course description:
The course is aimed for students who are new to the field of neuroscience. We outline the basic concepts and processes of brain function ranging from molecular to cognitive neuroscience. The course aims to teach students to understand the structure and function of neuronal communication in physiology and pathology at the molecular, cellular and system levels. They will learn about brain-related diseases and pharmacology of central nervous system disorders such as ADHD, addiction, schizophrenia, bipolar disorder and Parkinson’s disease. We will also introduce common methods to study brain function. Particularly, we will introduce electrophysiological, optogenetic, imaging, voltammetric and microdialysis techniques for the study of brain function. A high emphasis will be placed on critical discussions of most up-to-date methodology

Prerequisites:
Biological background, such as BS level knowledge of biochemistry, molecular and cellular biology, animal physiology.

 

Preclinical Pharmacology

Number of ECTS credits: 3
Course Classification: Science, Technology, and Engineering

Course description:
The course is aimed at students who are new to the field of drug discovery. We outline the basic concepts and processes of drug discovery with particular emphasize on preclinical pharmacology. The goal of this course is to give students with biological, chemical, physical, mathematical and engineering background the in-depth knowledge and understanding unraveling causative factors of disease and development of novel principles of pharmacological intervention. The course includes different stages of drug development process from target identification up to clinical studies: target validation studies, assay development, high throughput screening, data analysis, lead optimization, pharmacology of central nervous system disorders such as ADHD, addiction, schizophrenia, bipolar disorder and Parkinson’s disease, new frontiers in drug development in oncology, metabolic, infectious diseases, the use of transgenic animal models in pharmacology; GPCRs, kinases, transporters, ion channels and other molecular targets in pharmacology. We will also introduce common methods and modern techniques. A high emphasis will be placed on critical discussions of most up-to-date methodology.

Prerequisites:
Knowledge of biochemistry, molecular and cell biology, physiology and pharmacology.

Drug Discovery

Number of ECTS credits: 3
Course Classification: Science, Technology, and Engineering

Course Description:
The course is aimed at students who are new to the field of drug discovery. We outline the basic concepts and processes of drug discovery. The goal of this course is guidance through different stages of drug development process from bench findings to a clinical study.  Assay development, High Throughput Screening, data analysis, and lead optimization.
We will also introduce common methods and modern technics. A high emphasis will be placed on critical discussions of to-date methodology.
Animal in vivo models as essential element of drug target discovery, verification and mechanistic evaluation.  It covers all aspects of the field: principles of genetic modifications.

Upon completion of this course, the student will be able to:

  • Design target identification study;
  • Design cell based assay for High Throughput Screening and implement appropriate technic;
  • Data analysis and strategy for cherrypicks
  • Biochemical assay and compound mechanism of action
  • Critical review results and give short oral presentations on “generated data”
  • Design the study for structural activity relationship.
  • Animal dieses models
  • General toxicology

 

ФИО: Гайнетдинов Рауль Радикович

Занимаемая должность (должности): Профессор

Преподаваемые дисциплины: Поиск новых лекарств; Нейронаука

Ученая степень: Кандидат фармакологических наук, Второй Московский медицинский институт 1998; доктор фармакологических наук, Институт фармакологии, Российская Академия медицинских наук (РАМС), Москва, Россия, 1992

Ученое звание (при наличии): нет

Наименование направления подготовки и/или специальности: Фармакология

Данные о повышении квалификации и/или профессиональной переподготовке (при наличии): нет

Общий стаж работы: 23 года

Стаж работы по специальности: 23 года